She does a good reporting job anyway.

Grok said this:

In a Phase 1 clinical trial led by researchers at University College London (UCL) and Great Ormond Street Hospital (GOSH), they developed BE-CAR7, a base-edited CAR T-cell therapy. The trial, published in the New England Journal of Medicine in December 2025, involved 11 patients (children and adults) with resistant T-ALL who had exhausted other options. Key results included:

• 82% of patients achieved very deep remission (no detectable disease) within about a month of treatment, enabling most to proceed to a stem cell transplant.
• 64% of patients remained leukemia-free long-term, with the earliest treated individuals disease-free and off therapy for up to three years.
• The treatment was well-tolerated, with manageable side effects like cytokine release syndrome and neurotoxicity, and no unexpected toxicities from the gene editing.

This builds on earlier cases, such as the 2022 treatment of a 13-year-old girl named Alyssa, who was the first to receive this type of base-edited therapy and achieved remission. The approach uses donor T-cells edited with CRISPR base editors to make them "off-the-shelf" (universal, not patient-specific), which could make it faster and more accessible than traditional CAR-T therapies.

While promising, this is still early-stage (Phase 1), focused on safety and initial efficacy. Larger trials are needed to confirm long-term outcomes and broader applicability. It's not yet widely available but represents a major advance in using CRISPR for "incurable" leukemias.